Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-08-11 4:54 pm Purchase |
2022-04-29 | 13D | Verona Pharma plc VRNA |
Abingworth LLP | 21,313,822 4.400% |
249,600 (+1.18%) |
Filing History |
| 2022-07-11 4:30 pm Sale |
2022-07-01 | 13D | Sierra Oncology, Inc. SRRA |
Abingworth LLP | 0 0.000% |
-2,193,626 (Position Closed) |
Filing History |
| 2022-05-13 4:31 pm Purchase |
2022-05-03 | 13G | HilleVax, Inc. HLVX |
Abingworth LLP | 1,838,486 5.500% |
1,838,486 (New Position) |
Filing History |
| 2022-04-08 4:35 pm Purchase |
2022-03-29 | 13D | Soleno Therapeutics, Inc. SLNO |
Abingworth LLP | 1,224,558 15.300% |
521,598 (+74.20%) |
Filing History |
| 2022-04-07 4:39 pm Purchase |
2022-03-28 | 13D | Vera Therapeutics, Inc. VERA |
Abingworth LLP | 2,970,156 11.100% |
9,925 (+0.34%) |
Filing History |
| 2022-03-21 4:52 pm Unchanged |
2022-03-10 | 13D | Sierra Oncology, Inc. SRRA |
Abingworth LLP | 2,193,626 8.900% |
0 (Unchanged) |
Filing History |
| 2022-02-25 4:15 pm Purchase |
2021-12-16 | 13D | Exicure, Inc. XCUR |
Abingworth LLP | 47,229 6.500% |
5,538 (+13.28%) |
Filing History |
| 2022-02-14 4:17 pm Purchase |
2021-12-31 | 13G | Vaxcyte, Inc. PCVX |
Abingworth LLP | 4,183,716 7.900% |
14,998 (+0.36%) |
Filing History |
| 2022-02-10 5:00 pm Purchase |
2022-01-31 | 13D | Sierra Oncology, Inc. SRRA |
Abingworth LLP | 2,193,626 11.300% |
150,000 (+7.34%) |
Filing History |
| 2021-11-05 4:40 pm Purchase |
2021-11-05 | 13D | Sierra Oncology, Inc. SRRA |
Abingworth LLP | 2,043,626 12.600% |
7,874 (+0.39%) |
Filing History |
| 2021-10-04 4:10 pm Purchase |
2021-09-24 | 13D | Jasper Therapeutics, Inc. JSPR |
Abingworth LLP | 562,856 15.400% |
562,856 (New Position) |
Filing History |
| 2021-09-03 4:00 pm Purchase |
2021-08-25 | 13D | eFFECTOR Therapeutics, Inc. EFTR |
Abingworth LLP | 192,885 11.900% |
192,885 (New Position) |
Filing History |
| 2021-05-24 09:34 am Purchase |
2021-05-18 | 13D | Vera Therapeutics, Inc. VERA |
Abingworth LLP | 2,960,231 14.600% |
2,960,231 (New Position) |
Filing History |
| 2021-04-20 4:07 pm Purchase |
2021-04-13 | 13D | Reneo Pharmaceuticals, Inc. RPHM |
Abingworth LLP | 185,823 7.700% |
185,823 (New Position) |
Filing History |
| 2021-03-16 4:18 pm Sale |
2021-03-02 | 13D | Adicet Bio, Inc. ACET |
Abingworth LLP | 1,615,385 5.200% |
-25,336 (-1.54%) |
Filing History |
| 2021-03-08 08:30 am Purchase |
2021-03-02 | 13D | NuCana plc NCNA |
Abingworth LLP | 65,629 5.200% |
65,629 (New Position) |
Filing History |
| 2021-03-08 08:15 am Purchase |
2021-02-12 | 13G | Adicet Bio, Inc. ACET |
Abingworth LLP | 1,640,721 5.200% |
1,640,721 (New Position) |
Filing History |
| 2021-02-16 4:06 pm Purchase |
2020-12-31 | 13G | Vaxcyte, Inc. PCVX |
Abingworth LLP | 4,168,718 8.200% |
4,168,718 (New Position) |
Filing History |
| 2021-02-16 4:04 pm Sale |
2020-12-31 | 13G | Personalis, Inc. PSNL |
Abingworth LLP | 0 0.000% |
-4,462,452 (Position Closed) |
Filing History |
| 2020-10-16 4:05 pm Purchase |
2020-10-14 | 13D | Spruce Biosciences, Inc. SPRB |
Abingworth LLP | 1,792,518 7.700% |
1,792,518 (New Position) |
Filing History |